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1. Introduction 
Antibiotics are essential for modern medicine and as 
antibiotics are now becoming increasingly ineffective, effective 
treatment of an ever-increasing range of infections is 
threatened.[1, 2] As defence mechanism against β-lactam 
antibiotics, bacteria are able to produce β-lactamases that 
hydrolyse and inactivates the antibiotic.[3, 4] β-Lactamases are 
grouped into two super families, the serine dependent β-
lactamases (SBLs; Amber class A, C, and D) and metallo-β-
lactamases (MBLs; Amber class B).[5, 6] The MBLs are 
classified into three subclasses (B1, B2 and B3), with the 
majority of nosocomial MBLs belonging to the B1 subclass. This 
includes variants of the Verona integron-encoded metallo-β-
lactamase (VIM), the New Delhi metallo-β-lactamase (NDM), 
[7] and the German Imipenemase (GIM). The active site of the 
B1 MBLs is generally well preserved despite large variation in 
the second shell interacting residues. The active site holds two 
cationic zinc ions (Zn1, Zn2), as a metal co-factor of enzyme 
activity, which are coordinated by H116, H118 and H196 (Zn1) 
and D120, C221 and H263 (Zn2).[8, 9] Here and throughout the 
paper, the standard numbering scheme for class B β-lactamases is 
used. [10]. In general, the sequence identity among the class B1 
MBLs is low. For the enzymes used in this study, the sequence 
identity is 32% between VIM-2 and NDM-1, 28% for VIM-2 
versus GIM-1 and 24% between NDM-1 and GIM-1 (Figure S1 
in SI). 
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Bacterial resistance is compromising the use of β-lactam antibiotics including carbapenems. The 
main resistance mechanism against β-lactams is hydrolysis of the β-lactam ring mediated by 
serine- or metallo-β-lactamases (MBLs). Although several inhibitors of MBLs have been 
reported, none has been developed into a clinically useful inhibitor. Mercaptocarboxylic acids 
are among the most prominent scaffolds reported as MBL inhibitors. In this study, the 
carboxylate group of mercaptocarboxylic acids was replaced with bioisosteric groups like 
phosphonate esters, phosphonic acids and NH-tetrazoles. The influence of the replacement on 
the bioactivity and inhibitor binding was evaluated. A series of bioisosteres of previously 
reported inhibitors was synthesized and evaluated against the MBLs VIM-2, NDM-1 and GIM-
1. The most active inhibitors combined a mercapto group and a phosphonate ester or acid, with 
two/three carbon chains connecting a phenyl group. Surprisingly, also compounds containing 
thioacetate groups instead of thiols showed low IC50 values. High-resolution crystal structures of 
three inhibitors in complex with VIM-2 revealed hydrophobic interactions for the diethyl groups 
in the phosphonate ester (inhibitor 2b), the mercapto bridging the two active site zinc ions, and 
tight stacking of the benzene ring to the inhibitor between Phe62, Tyr67, Arg228 and His263. 
The inhibitors show reduced enzyme activity in Escherichia coli cells harboring MBL. The 
obtained results will be useful for further structural guided design of MBL inhibitors. 









The MBLs hydrolyze a broad spectrum of β-lactam antibiotics 
[3, 8, 11, 12] including the last resort antibiotics; the 
carbapenems. In addition, genes encoding certain MBLs are 
associated with mobile genetic elements and can spread across 
different types of Gram-negative bacteria.[7, 11] Inhibitors of 
SBLs are available clinically, [13] including the broad spectrum 
inhibitor avibactam. [14] Unfortunately, all SBL inhibitors lack 
activity against MBLs. [15] Although the search for MBL 
inhibitors started from mid 1990s, and a wide variety of scaffolds 
has been reported [16-18], clinically useful MBL inhibitors 
remain an elusive goal. 
In this study we decided to explore the use of thiol-based 
compounds as one of our strategies to gain increased knowledge 
on MBL inhibitors. Thiols have the potential to coordinate the 
zinc ions in the MBL active site, due to the thiophilic nature of 
zinc, and thereby preventing β-lactam hydrolysis. Some 
mercaptocarboxylic acids have been evaluated successfully 
against several MBLs [19-32], making this class of compounds 
an interesting starting point for further investigations. Our focus 
was to elucidate the effect of replacement of the carboxylate 
group in the promising mercaptocarboxylic acid scaffold with 
bioisosters on the bioactivity and enzyme-inhibitor binding. 
Bioisosteric replacement is a concept in medicinal chemistry to 
rationally improve the activity or physicochemical properties of 
biologically active compounds. [33] A structural element of a 
biological active compound is replaced with a substitute that 
maintain some of the properties of the parent structure, e.g. 
inhibitor binding to a biological target, while others are changed, 
e.g lipophilicity or steric size. Typical bioisosters of carboxylic 
acids include among others phosphonates, NH-tetrazoles and 
sulphonamides. [34]  
The target structures 2–4 (Scheme 1) were envisioned by 
substitution of the carboxylate group of the known 
mercaptocarboxylic acid inhibitor 1 [25, 35] with bioisosteric 
groups like phosphonate esters, phosphonic acids or NH-
tetrazoles, respectively. The carbon chain of the alkylphenyl 
substituent was varied (n = 2–4; Scheme 1) with the goal to 
evaluate the effect of chain length on hydrophobicity and 
bioactivity. The compounds and relevant intermediates from the 
synthetic pathway were simultaneous evaluated against the three 
MBLs VIM-2, NDM-1 and GIM-1 with the goal to find MBL 
inhibitors able to act on several different MBL subfamilies. For 
each target we have determined the IC50 value through enzyme 
inhibition assays and the effect of the inhibitors in whole cell E. 
coli assays with VIM-2, GIM-1 or NDM-1. Some inhibitors were 
also tested in a synergy assay with two or three clinical isolates 
from Pseudomonas aeruginosa, Klebsiella pneumoniae or 
Escherichia coli. The enzyme-inhibitor complexes of the best 
inhibitors were further evaluated by X-ray analysis and the 
impact from second shell interacting residues on ligand binding 
were examined. 
2. Results and discussion 
2.1. Chemistry 
For the purpose of this work, all compounds (Scheme 2 and 3) 
were prepared as racemic mixtures. Phosphonate ester 2a–c and 
phosphonic acid 3a–c analogues with differing chain lengths (n = 
2–4) were prepared according to the synthetic strategy presented 
in Scheme 2. Triethyl phosphonoacetate 5 was alkylated using 
potassium tert-butoxide (KOtBu) as base to afford the mono-
alkylated acetates 6a–c in moderate yields (45–73%). 
Chemoselective reduction of the ester in presence of the 
phosphonate was obtained with lithium borohydrid to provide the 
corresponding alcohols 7a–c. Subsequent mesylation followed by 
substitution with potassium thioacetate gave the thioacetates 8a–
c. Several methods for deprotection of the thioacetates were 
evaluated. [36-38] Best results were obtained by treatment with 
sodium methylthiolate (NaSMe) providing the free thiols 2a–c in 
 
 




Scheme 2. Synthesis of phosphonate and phosphonic acid containing thiol-based inhibitors. Reagents and conditions: a: n = 2; b: 
n = 3; c: n = 4; (a) R—Br, KOtBu, DMF, 0 °C, 6a: 62%, 6b: 73%, 6c: 45%; (b) LiBH4, THF, MW 80 °C for 10 min, 7a: 60%, 
7b: 95%, 7c: 56%; (c) MsCl, Et3N, DMAP, CH2Cl2, rt; (d) KSAc, DMF, rt.; 8a: 54%, 8b: 34%, 8c: 71% over two steps; (e) 
NaSMe, MeOH, –20 °C, 2a: 30%, 2b: 74%, 2c: 77%; (f) TMSBr, CH2Cl2, then MeOH, rt., 3a: 96%, 3b: 90%, 3c: 98%, 9a: 76%, 

























Scheme 3. Synthesis of NH-tetrazole containing thiol based inhibitors. Reagents and conditions: a: n = 1; b: n = 3; (a) R—Br, 
K2CO3, acetone, reflux; (b) 5% aq. NaOH, 13a: 51%, 13b: 21%; (c) TMSN3, n-Bu2SnO (20 mol%), 1,4-dioxane, MW 150 °C for 
50 min, 14a: 78%, 14b: 74%; (d) HSAc, DMF, 60 °C, 15a: 95%, 15b: 98%; (e) NaSMe, MeOH, –20 °C, 4: 74%; (f) 
cyclohexylthiol, DMF, 60 °C, 16: 93%.  
 
good yields (74–77%) and purity (>95% by HPLC). The 
phosphonates ester analogues 2, 7 and 8 were purified by normal-
phase flash column chromatography to >95% purity as 
determined by HPLC analysis. The diethyl phosphonates 2, 7 and 
8 were transferred to the corresponding phosphonic acid 
derivatives 3, 9 and 10, respectively, by treatment with 
trimethylsilyl bromide (TMSBr) followed by a MeOH quench. 
Purification of the phosphonic acid analogues 3, 9 and 10 could 
be achieved by washing with EtOAc/pentane to provide the target 
compounds with moderate to good yields and purity >95% as 
determined by HPLC analysis. 
The NH-tetrazole analogues 4, 15 and 16 were prepared as 
shown in Scheme 3. α-Substituted acrylonitriles 13a and 13b 
with varying chain lengths (n = 1, 3) were prepared by a 
procedure based on the work of Baraldi et al. [39]. Microwave 
promoted reaction of the acrylonitriles with trimethylsilyl azide 
with dibutyltinoxide as catalyst (20 mol%) [40] gave the 
corresponding NH-tetrazoles 14a and 14b (74–78% yield), which 
proved to be excellent Michael acceptors. The addition of 
potassium thioacetate resulted in the tetrazolyl thioacetates 15a 
and 15b in good yields (> 95 %), while the addition of 
cyclohexanethiol gave 16 (93% yield). Deprotection of the 
thioacetates by treatment with sodium methylthiolate (NaSMe) 
provided the free thiol 4 in moderate yield (74%) and purity 
>96% as determined by HPLC analysis. 
2.2. Characterization of inhibitor properties against VIM-2, 
GIM-1 and NDM-1 
The inhibitory activities of the mercaptocarboxylic acid 1c 
[25] and bioisosters 2a–c, 3a–c and 4, as well as several 
intermediates from the synthesis (7–10 a–c, 15a, 15b and 16) 
were determined by the half maximal inhibitory concentration 
(IC50) values (Table 1). For VIM-2 and GIM-1, the IC50 values 
were measured using nitrocefin as a reporter substrate, while IC50 
values for NDM-1 were measured with imipenem as reporter 
substrate. Nitrocefin is hydrolyzed by NDM-1 with a high 
catalytic efficiency and unsuitable as a reporter substrate for 
NDM-1 [41]. The influence of dimethyl sufoxide (DMSO) on the 
enzyme activity was investigated in the assay, and a 
concentration of 2.5% DMSO was tolerated without influencing 
the enzyme activity (data not shown). The IC50 values were 
determined by measuring the initial rate of the reactions with 
inhibitors at different concentration in a 2-fold dilution series, 
and were fitted to a dose-response curve (IC50 curves are given in 
Figure S2–S4 in SI). 
In order to validate our assay, the IC50 of the previously 
reported VIM-2 inhibitor 1c [25] was measured against VIM-2. 
We obtained an IC50 of 2.9 µM, which is in the same range as the 
reported value of 1.1 µM (Table 1).	  The difference in IC50 values 
is most likely due to different assay buffers and protein 
constructs. The new compounds showed IC50 values ranging 
from 0.38 to 133 µM with VIM-2, 0.18 to >5000 µM with GIM-
1 and 1.8 to 144 µM with NDM-1 (Tables 1 and S1 in SI). The 
synthetic intermediates 7–9 a–c, 15a and 15b did not have 
inhibitory activity (IC50 >10 µM, see Table S1 in SI) against any 
of the MBLs. Compounds 2a–c, 3a–c, 4, 10a–c and 16 showed 
activity at varying levels. In general, the inhibitors showed better 
IC50 values towards VIM-2 compared to GIM-1 and NDM-1, 
with the exception of inhibitor 2a, which had a ~five times lower 
IC50 for GIM-1 (0.18 µM) compared to VIM-2 (0.89 µM). 
Inhibitors 2a and 2b showed IC50 values ranging from 0.18-
2.2 µM for all three MBLs. The IC50s were within the same range 
for VIM-2 and GIM-1, and slightly increased for NDM-1 (1.8-
2.2 µM). Inhibitor 2c precipitated from the buffer solution and 
was not evaluated further. The results indicate that for the 
mercaptophosphonates 2, lengthening the side chain from two 
(2a) to three methylene groups (2b), did not have a great effect 
on the activity.  
While the mercaptophosponate esters 2 showed highest 
activity against GIM-1, the mercapto- and thioacetate phosphonic 
acids, 3 and 10, were more active towards VIM-2 and NDM-1 
than GIM-1. The IC50 values for thioacetate phosphonic acids 
10a–c ranged from 1.8 to 4.7 µM, and from 2.5 to 6.6 µM for 
VIM-2 and NDM-1, respectively. With GIM-1 the inhibitors 
10a–c showed slightly higher IC50 values of 12 to 26 µM. The 
same trend was seen with the mercaptophosphonic acids 3a and 
c, where the IC50 values for VIM-2 and NDM-1 were in the same 
range (7.8 and 8.6 µM with VIM-2 and 5.9 and 8.5 µM with 
NDM-1, respectively), while the values for GIM-1 were 2–4 fold 
higher (23 and 16 µM, respectively). A possible explanation for 
this might be that GIM-1 has a narrower active site compared to 
other MBLs due to the aromatic side chains Trp228 and Tyr233. 
[42] However, this does not explain the low IC50 values for 
inhibitors 2a and 2b.  
Substituting the carboxylic acid of compound 1 with a NH-
tetrazole (4) had a deteriorating effect on the inhibitory activity, 
while substitution with phosphonate esters and phosphonic acids 
groups led to similar (2 and 10) or improved (3) activity. 
Comparing the inactive alcohols 7 and 9 with the corresponding 
active thiols and thioacetates 2, 3 and 10 illustrates the
Table 1. Evaluation of compound 1 and bioisosteres thereof as inhibitors of VIM-2, GIM-1 or NDM-1 measured as inhibition 
concentrations (IC50) against purified enzyme and percent inhibition in E. coli SNO3 bacterial whole cell experiments. 
Compound  VIM-2a  GIM-1a  NDM-1b  
  IC50 (µM) % inhib IC50 (µM) % inhib IC50 (µM) % inhib 
 
1c (n = 4) 2.9 (1.1)c  - - 56 - 
 
2a (n = 2) 0.89 78 0.18 64 2.2 33 
2b (n = 3) 0.38 79 0.31 48 1.8 62 
2c (n = 4) pd pd pd pd Pd pd 
 
3a (n = 2) 7.8 92 23 37 5.9 42 
3b (n = 3) 33.2 95 28 46 7.1 45 
3c (n = 4) 8.6 94 16 31 8.5 42 
 
4 (n = 3) 28 67 68 25 12 16 
 
8a (n = 2) 133 17 18 25 nhe if 
8b (n = 3) 34 14 26 21 nhe if 
8c (n = 4) 20 12 13 25 nhe if 
 
10a (n = 2) 2.3 94 12 40 2.9 39 
10b (n = 3) 4.7 95 26 37 6.6 38 
10c (n = 4) 1.8 97 20 50 2.5 37 
 
16 (n = 3) 5 73 36 8 10 if 
a Reporter substrate used was nitrocefin (NCF); b Reporter substrate used was imipenem (IPM); c Values in parentheses as reported by Jin et al. [25];	  d p = 
precipitated in buffer and was not tested; e nh = no hydrolysis; f i = inactive.  
importance of the sulfur atom on the β-carbon for the inhibitor 
activity. However, activity seem to depend on a subtle 
combination of the sulfur atom and a carboxylic acid bioisoster 
as revealed when comparing the mercapto and thioacetate 
substituted phosphonate esters and phosphonic acids 2, 3, 8 and 
10. The mercapto substituted phosphonate esters 3 were the 
overall most active inhibitors, while the thioacetate substituted 
phosphonate esters 8 showed the lowest activity of all four. 
Surprisingly, the same trend was not observed for the pair of 
phosphonic acids 2 and 10. Here, the thiol 2 and the thioacetate 
10 inhibited the MBLs at the same level, which may indicate that 
the interaction of the phosphonic acid with the enzyme is more 
important for the activity than the interaction with the thiol. This 
interpretation would be in agreement with the previously reported 
observation that a mercaptophosphonic acid coordinated the 
MBL CphA by the two oxygen atoms of the phosphonic acid and 
not by the sulfur atom of the thiol. [43] 
The most active inhibitors showed activity in the low 
micromolar to high nano micromolar range for the racemic 
mixtures. In two recent studies, pure stereoisomers of the 
mercaptocarboxylic acids captopril [19] and bisthiazolidine [21] 
were found to display 10–100 times differences in inhibitory 
activity between different stereoisomers. This will most likely be 
the case for the compounds prepared in this work, and for future 
work this can be pursued. A large variation in inhibitory activity 
towards three B1 MBLs was observed, which indicates that these 
inhibitors do not fulfill the requirements for a broad-spectrum 
MBL inhibitor. 
2.3. Evaluation of inhibitors in bacterial cell assays 
To investigate if the inhibitors were active against MBLs in 
bacterial cells, two different assays were used. Initially, the 
inhibitors were tested in a whole cell assay using E. coli SNO3 
cells with blaVIM-2, blaGIM-1 or blaNDM-1 in pET26b(+) (Table 1). 
The inhibitory activity were measured as percent inhibition 
calculated by measuring the slope of the initial hydrolysis of the 
reporter substrates for up to 60 minutes, and the slope of a 
control without inhibitor present, according to equation 1. 
The percent inhibition for the most active compounds is 
shown in Table 1. High percent inhibition (>70%) was observed 
for several compounds, which indicates that the compounds pass 
the bacterial cell membrane of E. coli. The highest percent 
inhibition was observed for inhibitors 3a–c and 10 a–c in E. coli 
with VIM-2, with 92 to 95% and 94 to 97% inhibition, 
respectively. These results are in agreement with the low IC50 
values (1.8–8.6 and 33 µM). The inhibitory activity of 3a–c and 
10a–c was less pronounced with GIM-1 and NDM-1 resulting in 
an inhibition of around 30 to 50%, although the IC50 values 
against NDM-1 were in the same range as against VIM-2.  
The inhibitors 2a and 2b, showing lowest IC50 values, showed 
78% and 79% inhibition with VIM-2, respectively. While the 
percent inhibition of inhibitor 2a and 2b were 64% and 48% for 
GIM-1 and 33% and 62% for NDM-1, respectively. The 
phosphonate esters 2 were found to be more hydrophobic at pH 
7.1 (clogD = 3.4-3.8), which is the pH of the buffer medium, 
compared to the phosphonic acids 3 and 10 (clogD = -0.9-0.1), 
which probably results in poorer passive permeability [44] of the 
former explaining the lower % inhibition observed for these 
compounds. For NDM-1, inhibitor 2b was the best inhibitor in 















screening assay. Modification of 2 to alter the physicochemical 
properties may by a direction for further inhibitor improvement. 
Additionally, the inhibitors were tested for synergistic activity 
with meropenem against MBL-producing clinical strains, and 
effect from the inhibitors alone on the bacterial growth. The 
results are given in Table S2 in the SI. Disappointingly, synergy 
testing of the inhibitors with meropenem using bacterial strains 
from P. aeruginosa or K. pneumoniae did not show a lowering of 
the MIC. However, more promising results were observed when 
3b and 10b were tested against an E. coli strain with VIM-29. In 
these experiments, the MIC was lowered from 8–32 mg/L with 
only meropenem to 1 mg/L in presence of inhibitors (Table S2 in 
SI). Since VIM-2 has 90% sequence identity to VIM-29 it is 
likely to believe that VIM-2 could also be inhibited in a similar 
assay. In addition, the tested compounds were not toxic at high 
concentrations (>500 µM) to the three clinical cell lines included 
in this study (Table S2 in SI). 
2.4. Crystal structure complexes of VIM-2 with 2b, 10b and 10c 
To better understand the effects of bioisosteric substitution 
and to address the question of the coordinating properties of the 
phosponic acid group compared to the thiol, we attempted to 
obtain complex structures of the new inhibitors. Initial attempts 
to soak native crystals were found unsuccessful, whereas our new 
protocol for a DMSO free co-crystallization method [45] was 
successful for inhibitors 2b, 10b and 10c. Several more inhibitors 
were included in the experiment without providing satisfactory 
complexes. All the new VIM-2 complex structures have two 
protein molecules in the asymmetric unit, a αβ/βα fold with 
mobile loops adjacent to the active site, and there are two zinc 
ions in the active site, Zn1 bound to His116, His118 and His122 
and Zn2 coordinated by Asp120, Cys221 and His263. For all 
structures, the interactions in the best-defined protein chain will 
be described, and only discrepancies for other chain will be 
mentioned. 
The VIM-2_2b complex was the best-defined complex to 1.55 
Å (Table 2) and this complex was used to investigate the two 
different enantiomers. Herein, the (S)-form of the inhibitor 2b did 
not fit into the observed polder omit map (Figure 1A), whereas 
for the (R)-form (Figure 1B), the substituents at the stereogenic 
center are all defined within the polder omit map. Therefore, we 
anticipate that VIM-2 is selectively binding the (R)-enantiomer of 
2b, since the CH2-SH group, the CH2-CH2 chain and the 
phosphonate ester are defined inside both the polder omit and the 
final 2Fo-Fc map (Figure 1B, C). The three-dimensional 
arrangement of substituents on the stereogenic centre of (R)-2b 
(Figure 2) is in agreement with the reported complex of VIM-
2_1b [35] selectively bound to (S)-1b. Note that the difference in 
naming of the stereoisomers ((S)-1b versus (R)-2b) relates to 
differences in priority according to the Khan-Ingold-Prelog rules 
(for 1b: CH2SH > CO2H while for 2b: P(O)(OH)2 > CH2SH) not 
to inversion of the stereocenter. For both VIM-2_10b and 10c 
structures, the (R)-configuration fits best in the polder omit and 
2Fo-Fc maps (Figure 1D–I), but less convincing than for the 
highest resolved VIM-2_2b complex (Figure 1A–C). This 
indicates that for the structurally related compounds of this study 
the three-dimensional arrangement corresponding to the (R)-
configuration probably leads to inhibitors with improved binding 
and inhibition properties. 
Table 2. X-ray data collection and crystallographic refine-
ment statistics for VIM-2 complexes of 2b, 10b and 10c. 
Values in parenthesis are for the highest resolution shell. 
 VIM-2_2b VIM-2_10b VIM-2_10c 
PDB entry    
X-ray source ID29, ESRF ID29, ESRF ID29, ESRF 
Data collection 
statistics 
   
Space group C2 P212121 P212121 
























Wavelength (Å) 0.97625 0.97625 0.97625 
No. unique reflections 54949 (5447) 45 000 (4421) 56573 (5666) 
Multiplicity 2.0 (1.9) 6.5 (6.7) 6.4 (6.3) 
Completeness (%) 93.58 (93.51) 99.93 (99.98) 94.12 (92.38) 
Mean (<I> /<σI>) 8.16 (1.92) 14.60 (2.30) 10.80 (1.61) 
R-merge a 0.064 (0.417) 0.073 (0.791) 0.102 (0.925) 
CC 1/2 0.995 (0.679) 0.999 (0.785) 0.997 (0.634) 






Wavelength (Å) 0.97625 0.97625 0.97625 
No. unique reflections 54949 (5447) 45 000(4 421) 56573 (5666) 
Multiplicity 2.0 (1.9) 6.5 (6.7) 6.4 (6.3) 
Completeness (%) 93.58 (93.51) 99.93 (99.98) 94.12 (92.38) 
Mean (<I> /<σI>) 8.16 (1.92) 14.60 (2.30) 10.80 (1.61) 
R-merge a 0.064 (0.417) 0.073 (0.791) 0.102 (0.925) 
CC 1/2 0.995 (0.679) 0.999 (0.785) 0.997 (0.634) 
Wilson B-factor (Å2) 14.84 27.24 20.49 
Refinement statistics    
Resolution (Å) 24.94-1.55  25-1.85 25-1.67  
R-factor (all 
reflections) 
0.1575 0.1662 0.1778 
R-freeb 0.2006 0.2039 0.2140 
RMSD bond lengths 
(Å) 
0.011 0.013 0.011 
RMSD bond angles (°) 1.31 1.32 1.32 
Ramachandran 
favored (%)  
98.0 97.0 97.0 
Ramachandran outliers 
(%) 
0.46 0.47 0.95 
Clashscore 5.50 3.00 5.62 
Average B-factor (Å2)     
 All atoms 20.8 36.5 27.4 
 Chain A/B 20.6/20.6 32.6/37.2 25. 3/26.18 
 Solvent 34.0 47.9 37.0 
 Ligand A /B 40.3/32.8 47.5/58.5 63.04/64.24 
Mean occupancy  
 Zn1 A/B  










 Ligand A/B 1.0/0.9 0.7/0.8 0.9/0.9 
 
 
Figure 1: Observed electron density maps for the new inhibitors with polder omit maps depicted at 2.5σ (green), 2Fo-Fc maps at 1.0 σ (blue) and Fourier 
difference maps (Fo-Fc) at 4.0 σ (green) and -4.0 σ (red). The polder omit maps for VIM-2 with the inhibitors 2b, 10b and 10c in (S)-form (left panels), (R)-form 
(middle panels) and the final 2Fo-Fc map (right panels) are displayed. The zinc ions (orange) and adjacent water (red) are shown, and hydrogen bonds are shown 
as red dashed lines. 
 
 
Figure 2: A-C) Stereochemical view of the enantiomeric form of 1b, 2b, 10b and 10c coordinated and bound to VIM-2. D) Overlay of VIM-2_2b (cyan) and 
previously reported VIM-2_1b [35] (grey).
In the VIM-2_2b crystal structure there are hydrogen bonds 
from the OAE atom of the P=O double bond in compound 2b to 
the Asn233 sidechain (d(OAEligand …ND2N233) = 2.84 Å) and 
from the SH group to both zinc ions (d(Sligand …Zn1/Zn2) = 
2.30/2.30 Å). Further, the benzene ring of compound 2b is 
sandwiched between Arg228 and Tyr67, making T-shaped π-π 
stacking interactions with Tyr67 and cation-π interactions with 
the positively charged Arg288 in a parallel manner. The benzene 
ring is also in a T-shaped stacking conformation with His263. 
Additionally, the ethyl groups of the phosphonate ester make 
hydrophobic interactions with Phe61, Tyr67, Trp87, and CA and 
CB carbon atoms of Asp119 (Figure 3A). These two ethyl 
groups are absent in the corresponding phosphonic acids 3, which 
display higher IC50 values (7.8–33.2 µM) towards VIM-2 than 
the phosphonate esters 2 (0.38–1.7 µM) (Table1), indicating that 
the phosphonic acid group is not involved in corresponding 
favorable interactions.  
Comparison of the VIM-2_2b structure with the previously 
reported complex of VIM-2_1b [35] (Figure 2D) showed that 
the sulfur atom of thiol 2b is bridging the zinc(II) atoms of VIM-
2 resembling the earlier reported complex of VIM-2_1b and 
numerous other thiol-B1 MBL complex structures. [19, 23, 28, 
35, 46-49] Also, the propylphenyl chains of 1b and 2b occupy 
the same region in VIM-2. Still there is a T-shaped stacking for 
Phe61 and phenyl in our new 2b complex, and a face-to-face 
more parallel π-π stacking for 1b (PDB ID: 2YZ3) [35]. Both the 
carboxyl group of 1b and the phosphonate P=O of 2b are 
forming hydrogen bonds with the ND2 atom in the side chain of 
Asn233. The slightly different orientations of the inhibitors 1b 
and 2b may be attributed to the hydrophobic interactions of the 
two ethyl groups of 2b with residues Phe61, Tyr67, Trp87, and 
CA and CB carbon atoms in the Asp119 (Figure 3A). 
The resolution of the VIM-2_10b structure is 1.85 Å, and this 
inhibitor was refined in the (R)-form since this fitted best in the 
observed electron density maps (Figure 1D, E). In the final 
electron density maps the orientation of the thioacetate group is 
described adequately but the width of the electron density is 
indicating flexibility and there is positive election in the Fo-Fc 
map. This additional density could be ascribed to the hydroxyl 
ion between Zn1 and Zn2, but this could not be modeled and is 
thus left out in the final structure. Further, there is additional 
unmodeled density in elongation of the methyl group of the 
thioacetate of 10b. The complex of VIM-2_10c is very similar to 
VIM-2_10b. Still, for the VIM-2_10c structure, a hydroxyl ion 
bridging Zn1 and Zn2 in both chain A and chain B could be 
modeled, but the methylene chain is not well defined in the 
electron density and displays high B-factors (Table 2, Figure 1F 
and 1G). 
From the VIM-2_10b and _10c complex structures, it is clear 
that the sulfur atom of the thioacetate is binding the zinc atoms 
differently when compared to typical thiol complexes e.g. the 
VIM-2_2b complex. In both the VIM-2_10b and 10c structures, 
the thioacetate interacts with Zn2 and the ND2 atom of Asn233 
through the sulfur atom, with His263 and through a water 
molecule to the guanidinium group of Arg228 (Figure 3B and 
3C, respectively). In VIM-2_10b the S-atom is close to both zinc 
ions (d(Sligand …Zn1/Zn2) = 2.96/3.22 Å) (Figure 3B), while for 
VIM-2_10c, the S to zinc distances are longer (d(Sligand 
…Zn1/Zn2) = 3.29/4.02 Å; Figure 3C). In both structures, the 
phosphonic acid is adjacent to Trp87 and interacting with the side 
chain of Asn233. These findings differ from the reported CphA–
mercaptophosphonic acid complex, in which the Zn was 
coordinated by two oxygen atoms of the phosphonic acid and not 
 
Figure 3. Interactions found in the VIM-2_2b (A), VIM-2_10b (B) and 
the VIM-2_10c (C) complexes. For the two latter (10b and 10c), residue 
Phe61 is situated above the paper plane and left out of the figure for 
simplification. 
 
by the sulfur atom of the thiol. [43] However, CphA belongs to 
the B2 MBL subclass containing one zinc ion in the active site 
compared to two zinc ions for B1 MBLs, which may explain the 
observed differences. In addition, the benzene ring of compound 
10b is more parallel to Tyr67 compared to VIM-2_2b structures, 
and both Arg228 and the main chain of Gly232 are stacking at 
the opposite side, and His263 in a T-shaped orientation. 
Furthermore, the position of residue Phe61 differs 
significantly between complexes of 2b and 10b/c. In the 
complexes of 10b and 10c, the residue Phe61 is moved and 
closed down on the inhibitors interacting with the phosphonic  
 
Figure 4. Ribbon diagrams (left panels) and calculated electrostatic surfaces (right panels) of VIM-2 (A, B), GIM-1 (C, D) and NDM-1 (E, F). In panel F, the 
structure of ampicillin (orange) in complex with NDM-1 (PDB ID: 4RLO) is given. Residues discussed or being highly charged are labeled. 
 
acid group, whereas in the 2b structure Phe61 is in a slight more 
open conformation interacting with the ethyl groups (Figure 4A). 
2.5. Modeling of complexes with GIM-1 and NDM-1 
The sequence identity between the three MBLs included in this 
study is 32% (VIM-2 versus NDM-1), 28% (VIM-2 versus GIM-
1) or 24% (NDM-1 versus GIM-1) (Figure S1). Low sequence 
identity is also found between the second shell sphere residues 
that constitute the active site together with the six conserved zinc 
binding residues (116, 118, 196, 120, 221, 263). The impact from 
these second shell interacting residues on ligand binding with 
GIM-1 and NDM-1 was examined by modeling the inhibitor 
binding based on the VIM-2 complexes obtained. 
When superimposing the new VIM-2 complexes with 
inhibitors 2b, 10c and 10b onto the GIM-1 structure (Figure 4C, 
D) (PDB ID: 2YNW; [50]), it becomes clear that the R2 binding 
sites accommodating the phenyl group of the inhibitors are very 
different. For GIM-1, both Trp228 and Tyr64 confine the R2 site 
making it smaller and more hydrophobic. Our reported IC50 
values for compounds 2 and 10 are not significantly different 
for the longest (n = 4) compared to the shortest (n = 2) inhibitors 
in a series (Table 1). This indicates that similar favorable T-
shaped stacking from Trp228 and cation-π interactions from 
Arg224 to the phenyl groups of the inhibitors are possible for all 
compounds within a series. Several conformations are described 
for Trp228 in the native GIM-1 crystal structures, [50] which all 
can contribute to the described inhibitor interactions. 
Furthermore, residue 233 is a tyrosine in GIM-1 and the polar 
interactions observed in VIM-2_2b, 10b and 10c from Asn233 to 
the P=O group cannot be formed. Still the low IC50 of for 2a of 
0.18 µM and 64% inhibition towards GIM-1 (Table 1) tells that 
it is possible to inhibit GIM-1 in a cell based assay.  
The new synthetized inhibitors are less efficient towards E. 
coli SNO3 cell with NDM-1, but 2a, 2b and 10a-c show low IC50 
values with pure enzyme (1.8–6.6 µM; Table 1). As with VIM-2 
(and in contrast to GIM-1), NDM-1 has an Asn233 residue, 
which can bind the inhibitors through the P=O group as for VIM-
2. However, hydrophobic stabilization of the phenyl rings of the 
inhibitors is limited for NDM-1 as the R2 binding site consists of 
Ala228 and Lys224, where the lysine residue is shorter than 
Arg228 (VIM-2) and Arg224 (GIM-1). Further, Phe63 in NDM-1 
is too far away to reach down to the phenyl groups of the 
modelled 2b, 10b and 10c inhibitor complexes (Figure 4E). In 
the reported complex structure of NDM-1 with hydrolyzed 
ampicillin (PDB ID: 3Q6X; Figure 4F), the substrate interacts 
with Ile64and Val73 (in the R2 site), and the “R1” part of the 
ampicillin with Met60 and Gln119. The NDM-1 binding site is 
more hydrophobic and also different from both VIM-2 and GIM-
1 with few conserved second shell residues, thus the design of an 
inhibitor hitting all three MBL targets is challenging. 
3. Conclusion 
Our bioisosteric approach on designing new metallo-β-
lactamase inhibitors was found successful with low dose rate 
measurement for the 2 series of inhibitors (IC50 = 0.18–2.2 µM) 
towards all three enzymes, VIM-2, GIM-1 and NDM-1. For the 
cell-based assay with a β-lactamase-negative E. coli SNO3 cells 
inducing expression of one MBL, the best inhibitors were the 3 
and 10 series. The three new crystal structures of VIM-2 with 2b, 
10b or 10c, reveal energetic favorable cation-π interactions from 
Arg228, and stacking from Tyr67 and Phe61 with the phenyl ring 
of the inhibitors. Asn233 in VIM-2 is also contributing with polar 
interactions to the P=O group (2b) and sulphur atom (10b, 10c). 
Disappointingly, no synergistic effect was seen in P. aeruginosa 
nor in K. pneumoniae bacterial strains, but some effects on a 
clinical isolate from E. coli with VIM-29 were observed for 3b 
and 10b showing reduced MIC. A broad inhibitor hitting VIM-2, 
GIM-1 and NDM-1 was not found, but one promising hit is the 
thioacetate phosphonic acid 10b, which seems to target both 
VIM-2 and NDM-1. The reported VIM-2_10b structure is 
therefore a valuable starting point for a structure-guided design 
of an inhibitor targeting both VIM-2 and NDM-1 simultaneously. 
4. Experimental 
4.1. Chemistry 
All reagents and solvents were purchased from commercial 
sources and used as supplied unless otherwise stated. Compounds 
1c and 17 were prepared according to the literature. [36] 
Reactions were monitored by thin-layer chromatography (TLC) 
with Merck pre-coated silica gel plates (60 F254). Visualization 
was accomplished with either UV light or by immersion in 
potassium permanganate or phosphomolybdic acid (PMA) 
followed by light heating with a heating gun. Purification of 
reactions was carried out by flash column chromatography using 
silica gel from Merck (Silica gel 60, 0.040 - 0.063 mm). 
Analytical HPLC was carried out on a Purity analysis was carried 
out on Waters Acquity UPLC® BEH C18 (1.7 µm, 
2.1 × 100 mm) column on a Waters Acquity I-class UPLC with 
Photodiode Array Detector. NMR spectra were obtained on a 400 
MHz Bruker Avance III HD equipped with a 5 mm SmartProbe 
BB/1H (BB = 19F, 31P-15N). Data are represented as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q 
= quartet, p = pentet, m = multiplet), coupling constant (J, Hz) 
and integration. Chemical shifts (δ) are reported in ppm relative 
to the residual solvent peak (CDCl3: δH 7.26 and δC 77.16; 
Methanol-d4: δH 3.31 and δC 49.00). 31P NMR spectra were 
recorded using an insertion NMR tube filled with PPh3 (δ = -5.4 
ppm) solution in C6D6 as a reference. Positive ion electrospray 
ionization mass spectrometry was conducted on a Thermo 
electron LTQ Orbitrap XL spectrometer. IR spectra were 
recorded with Model Varian 7000e FT-IR spectrometer. 
4 .1 .1 .  Prepara t ion  and  spec troscopic  da ta  o f  2 -
(Mercaptomethy l ) -6 -pheny lhexanoic  ac id  (1c ) :  
The title compound 1c was prepared as reported in the 
literature. [36] The final deacetylation was performed according 
to the general procedure (see chapter 4.1.5). The preceding 
thioacetate (1.67 mmol, 468 mg, 1 equiv) in methanol (6 mL) 
was treated with 1M NaSMe in MeOH (3.4 mmol, 3.4 mL, 2 
equiv). Reaction time was 1.5 h. Column chromatography (6% 
MeOH: CH2Cl2) gave the product 1c as a white solid (1.23 mmol, 
290 mg, 74%) of high purity (>95% as determined by HPLC). 1H 
NMR (400 MHz, Chloroform-d) δ 10.85 (s, 1H), 7.30-7.16 (m, 
4H), 2.79-2.74 (m, 1H), 2.68-2.60 (m, 2H), 1.75-1.66 (m, 4H), 
1.53 (t, J = 8.5 Hz, 1H), 1.44 (q, J = 7.8 Hz, 2H). 13C NMR (101 
MHz, Chloroform-d) δ 180.7, 142.2, 128.4, 128.3, 125.8, 125.7, 
49.0, 35.6, 31.2, 31.2, 30.9, 26.6, 25.6. HRMS (ESI): Calcd. for 
C13H17O2S [M+H]+ 237.0954; found 237.0944. The NMR and 
MS data were in accordance with the literature. [36] 
4 .1 .2 .  Genera l  procedure  for  the  a lky la t ion  o f  
t r ie thy l  phosphonoace ta te  (6a–c )  
A solution of ethyl-2-(diethoxyphosphoryl) acetate 5 in DMF 
(25mL/mol) was stirred at 0 ˚C. The base was added and the 
solution was continued to stir for 20 min before the alkyl halide 
was added drop wise. The reaction mixture was allowed to warm 
to room temperature and then heated at 60 ˚C for 18 hours. After 
cooling the reaction mixture was acidified with 10% citric acid 
and extracted with diethyl ether (3 x 30 mL). The combined 
organic phases were washed with H2O (3 x 30 mL), brine (1 x 30 
mL) and dried over Na2SO4. The product 6a–c was purified with 
column chromatography using 2:1 diethyl ether/pentane as 
eluent. 
4 .1 .2 .1 .  Ethy l  2 - (d ie thoxyphosphory l ) -4 -
pheny lbu tanoate  (6a ) :   
Potassium tert-butoxide (0.028 mol, 3.15 g, 1 equiv), ethyl 2-
(diethoxyphosphoryl) acetate (0.028 mol, 6.30 g, 1 equiv) and 1-
bromo-2-phenylethane (0.028 mol, 5.18 g, 1 equiv) gave 6a 
(0.018 mol, 5.76 g, 62%) as a pale yellow oil. 1H NMR (400 
MHz, Chloroform-d) δ 7.28-7.26 (m, 2H), 7.21-7.16 (m, 3H), 
4.23-4.20 (m, 2H), 4.14-4.07 (m, 4H), 2.96 (ddd, J = 22.9, 11.0, 
3.6 Hz, 1H), 2.79-2.69 (m, 1H), 2.64-2.56 (m, 1H), 2.35-2.26 
(m), 2.18-2.12 (m, 1H), 1.30-1.28 (m, 9H). 13C NMR (101 MHz, 
Chloroform- d) δ 169.5 (d, J = 5.0 Hz), 140.9, 128.9 (d, J = 10.7 
Hz), 126.7, 63.2 (dd, J = 8.4, 6.7 Hz), 61.9, 46.2, 44.9, 34.9 (d, J 
= 15.4 Hz), 29.1 (d, J = 4.4 Hz), 16.9 (dd, J = 6.1, 2.3 Hz), 
14.7.31P NMR (162 MHz, Chloroform-d): δ 23.0. HRMS (ESI): 
Calcd. for C16H26O5P [M+H]+ 329.1512; found 329.1519. 
4 .1 .2 .2 .  Ethy l  2 - (d ie thoxyphosphory l ) -5 -
pheny lpen tanoate  (6b ) :  
Potassium tert-butoxide (0.064 mol, 7.18 g, 0.8 equiv), ethyl 
2-(diethoxyphosphoryl) acetate (0.08 mol, 20.01 g, 1 equiv) and 
1-bromo-3-phenylpropane (0.064 mol, 12.71 g, 0.8 equiv) gave 
6b (0.046 mol, 15.89 g, 73%) as a pale yellow oil. 1H NMR (400 
MHz, Chloroform-d) δ 7.29-7.24 (m, 2H), 7.19-7.14 (m, 3H), 
4.28-4.08 (m, 6H), 2.96 (ddd, J = 22.7, 10.9, 3.8 Hz, 1H), 2.63 (t, 
J = 7.8 Hz, 2H), 2.07-2.02 (m, 1H), 1.92-1.89 (m, 1H), 1.72-1.65 
(m, 2H), 1.34-1.26 (m, 9H). 13C NMR (101 MHz, Chloroform-d) 
δ 169.1 (d, J = 4.8 Hz), 141.8 (d, J = 29.8 Hz), 128.3-128.2 (m), 
125.8 (d, J = 29.8 Hz), 62.6 (dd, J = 9.1, 6.6 Hz), 61.3, 46.3, 
44.9, 35.3, 30.1 (d, J = 14.9 Hz), 26.6 (d, J = 4.8 Hz), 16.3 (dd, J 
= 5.9, 2.7 Hz), 14.1. 31P NMR (162 MHz, Chloroform-d): δ 23.1. 
HRMS (ESI): Calcd. for C17H27O5NaP [M+Na]+ 365.1488; found 
365.1484. 
4 .1 .2 .3 .  Ethy l  2 - (d ie thoxyphosphory l ) -6 -
pheny lhexanoate  (6c ) :  
Potassium tert-butoxide (0.014 mol, 1.55 g, 0.7 equiv), ethyl-
2-(diethoxyphosphoryl) acetate (0.019 mol, 4.25 g, 1 equiv) and 
1-bromo-4-phenylbutane (0.013 mmol, 2.83 g, 0.7 equiv) gave 6c 
(0.009 mol, 3.37g, 73%) as a yellow oil. 1H NMR (400 MHz, 
Chloroform-d) δ 7.33-7.28 (m, 2H), 7.22-7.15 (m, 3H), 4.27-4.12 
(m, 6H), 2.96 (ddd, J = 22.5, 11.0, 3.8 Hz, 1H), 2.65-2.58 (m, 
2H), 1.72-1.68 (m, 1H), 1.68-1.65 (m, 1H), 1.38-1.36 (m, 2H) 
1.3-1.25 (m, 11H). 13C NMR (101 MHz, Chloroform-d) δ 169.3 
(d, J = 4.8 Hz), 142.2, 128.3 (d, J = 8.7 Hz), 125.7, 62.7(t, J = 
6.6, 14.6 Hz), 61.3, 46.5, 45.2, 35.5, 30.9, 28.1 (d, J = 15.0 Hz), 
26.9 (d, J = 4.9 Hz), 16.4 (dd, J = 6.1, 3.2 Hz), 14.2. 31P NMR 
(162 MHz, Chloroform-d): δ 23.3. HRMS (ESI): Calcd. for 
C18H30O5P [M+H]+ 357.1825; found 357.1822. 
4 .1 .3 .  Genera l  procedure  for  the  reduc t ion  o f  
a lky la ted  t r ie thy l  phosphonoace ta te  (7a–c )  
LiBH4 was dissolved in THF (2 mL/ mmol) at 0 ˚C and slowly 
added to the ester 6a–c in THF at 0 ˚C. The suspension was 
stirred at room temperature for 30 minutes and irradiated at 80 ˚C 
for 10 min. The mixture was cooled to RT and slowly diluted 
with MeOH and stirred for 30 min until excess of the LiBH4 was 
quenched. The mixture was acidified with 10% citric acid, 
saturated with NaCl and the product was extracted with diethyl 
ether. The organics were dried over Na2SO4, filtered and 
concentrated in vacuum. The product 3a–c was purified with 
column chromatography with 5% MeOH: CH2Cl2.  
4 .1 .3 .1 .  Die thy l  1 -hydroxy-4-pheny lbu tan-2-
y lphosphonate  (7a ) :  
Ethyl 2-(diethoxyphosphoryl)-4-phenylbutanoate 6a (1.6 
mmol, 0.53 g, 1 equiv) and LiBH4 (4.8 mmol, 0.12 g, 3 equiv) 
gave 7a (1.0 mmol, 0.28 g, 60%) as a colorless oil. 1H NMR (400 
MHz, Chloroform-d) δ 7.31-7.26 (m, 2H), 7.21-7.18 (m, 3H), 
4.14-4.07 (m, 4H), 3.89-3.79 (m, 2H), 3.15-3.12 (m, 1H), 2.81 
(ddd, J = 14.5, 9.2, 5.7 Hz, 1H), 2.69 (ddd, J = 13.8, 9.4, 6.6 Hz, 
1H), 2.01-1.98 (m, 2H), 1.97-1.83 (m, 1H), 1.35-1.29 (m, 6H). 
13C NMR (101 MHz, Chloroform-d) δ 141.1, 128.4 (d, J = 5.7 
Hz), 126.1 , 61.9 (t, J = 6.7 Hz), 60.7 (d, J = 5.5 Hz), 39.1 , 37.7 , 
33.5 (d, J = 11.1 Hz), 27.0 (d, J = 3.5 Hz), 16.5 (t, J = 5.5 Hz). 
31P NMR (162 MHz, Chloroform-d): δ 33.3. HRMS (ESI) Calcd. 
for C14H24O4P [M+H]+ 287.1407; found 287.1408.  
4 .1 .3 .2 .  Die thy l  1 -hydroxy-5-pheny lpen tane-2-
y lphosphonate  (7b ) :  
Ethyl 2-(diethoxyphosphoryl)-5-phenylpentanoate 6b (4.7 
mmol, 1.60 g, 1 equiv) and LiBH4 (0.012 mol, 255 mg, 2.5 
equiv) gave 7b (4.5mmol, 1.34g, 95%) as a colorless oil. 1H 
NMR (400 MHz, Chloroform-d) δ 7.29-7.25 (m, 2H), 7.19-7.16 
(m, 3H), 4.15-4.08 (m, 4H), 3.82-3.77 (m, 2H), 3.46 (s, 1H), 2.62 
(t, J = 7.4 Hz, 2H), 1.81-1.71 (m, 1H), 1.68-1.66 (m, 2H), 1.66-
1.50 (m, 1H), 1.31 (m, 6H). 13C NMR (101 MHz, Chloroform-d) 
δ 141.8, 128.3 (d, J = 5.7 Hz), 125.7, 61.8 (dd, J = 13.1, 6.8 Hz), 
60.5 (d, J = 4.4 Hz), 39.9, 38.5, 35.6, 29.2 (d, J = 10.4 Hz), 25.1 
(d, J = 3.7 Hz), 16.4 (d, J = 5.5 Hz). 31P NMR (162 MHz, 
Chloroform-d): δ 33.0. HRMS (ESI) Calcd. for C15H26O4P 
[M+H]+ 301.1563; found 301.1566.  
4 .1 .3 .3 .  Die thy l  1 -hydroxy-6-pheny lhexane-2-
y lphosphonate  (7c ) :   
Ethyl 2-(diethoxyphosphoryl)-6-phenylhexanoate 6c (4.21 
mmol, 1.5 g, 1 equiv) and LiBH4 (10.53 mmol, 229 mg, 2.5 
equiv) gave 7c (2.34 mmol, 737 mg, 56%) as a colorless oil. 1H 
NMR (400 MHz, Chloroform-d) δ 7.21-7.17 (m, 2H), 7.11-7.08 
(m, 3H), 4.08-4.02 (m, 4H), 3.78-3.65 (m, 2H), 2.56-2.52 (m, 
2H), 1.91-1.87 (m, 1H), 1.63-1.53 (m, 3H), 1.46-1.44 (m, 2H), 
1.35-1.34 (m, 1H), 1.25 (t, J = 7.1 Hz, 6H). 13C NMR (101 MHz, 
Chloroform-d) δ 142.4, 128.5-128.4 (m), 125.9, 62.1 (dd, J = 
13.6, 6.9 Hz), 60.9 (d, J = 5.7 Hz), 40.0, 38.7, 35.8, 31.4, 27.3 (d, 
J = 11.0 Hz), 25.3 (d, J = 3.8 Hz), 16.6. 31P NMR (162 MHz, 
Chloroform-d): δ 33.3. HRMS (ESI): Calcd. for C16H28O4P 
[M+H]+ 315.1720; found 315.1723. 
4 .1 .4 .  Genera l  procedure  for  th ioace ty la t ion  (8a–c )  
Compound 7a–c (1 equiv) was dissolved in CH2Cl2 (5 
mL/mmol) and added triethylamine (1.05 equiv) and a catalytic 
amount of 4-dimethylaminopyridine (DMAP). The mixture was 
stirred for 5 minutes at RT, before methanesulfonyl chloride 
(1.05 equiv) was slowly added. The reaction mixture was stirred 
for 3–24 hr at RT. The solvent was evaporated, and the 
remaining crude was quenched with 100mL aq. NH4Cl and 
extracted with diethyl ether, dried over Na2SO4, filtered, and 
evaporated. To the crude was added an excess (7-10 equiv) of 2 
M potassium thioacetate in DMF and stirred overnight at RT. 
The brown suspension was quenched with aq. NH4Cl (100 mL) 
and the product was extracted with diethyl ether (3 x 30 mL). The 
combined organic layers were washed with H2O (3 x 50 mL), 
dried over Na2SO4 and concentrate to yield an orange oil. The 
crude was purified with column chromatography using 5–15% 
MeOH:CH2Cl2 as eluent. 
4 .1 .4 .1 .  S-2- (Die thoxyphosphory l ) -4 -pheny lbu ty l  
e thane th ioa te  (8a ) :  
Diethyl 1-hydroxy-4-phenylbutan-2-ylphosphonate 7a (2.8 
mmol, 825 mg, 1 equiv), triethylamine (2.9 mmol, 355 mg, 1.05 
equiv), methanesulfonyl chloride (2.9 mmol, 355 mg, 1.05 
equiv), DMAP (catalytic amount) and potassium thioacetate 
(20.3 mmol, 2.31 g, 7 equiv) gave 8a (1.5 mmol, 520 mg, 54%) 
as an orange oil. 1H NMR (400 MHz, Chloroform-d) δ 7.33-7.30 
(m, 2H), 7.25-7.22 (m, 3H), 4.23-4.13 (m, 4H), 3.44-3.39 (m, 
1H), 3.08-3.05 (m, 1H), 2.85-2.81 (m, 2H), 2.37 (s, 3H), 2.10-
2.05 (m, 2H), 1.93-1.91 (m, 1H), 1.41-1.36 (m, 6H). 13C NMR 
(101 MHz, Chloroform-d) δ 195.3, 141.4, 128.5 (d, J = 12.7 Hz), 
126.0, 61.9 (dd, J = 6.8, 2.5 Hz), 36.4, 35.1 , 33.5 (d, J = 7.5 Hz), 
30.6 , 29.6 (d, J = 3.3 Hz), 28.3 (d, J = 2.0 Hz), 16.5 (d, J = 5.9 
Hz). 31P NMR (162 MHz, Chloroform-d): δ 30.3. HRMS (ESI): 
Calcd. for C16H26O4PS [M+H]+ 345.1285; found 345.1289.  
4 .1 .4 .2 .  S-2- (d ie thoxyphosphory l ) -5 -pheny lpen ty l  
e thane th ioa te  (8b ) :  
Diethyl 1-hydroxy-5-phenylpentane-2-ylphosphonate 7b (0.93 
mmol, 289 mg, 1 equiv), triethylamine (0.98 mmol, 111 mg, 1.05 
equiv), methanesulfonyl chloride (0.98 mmol, 111 mg, 1.05 
equiv), DMAP (catalytic amount) and potassium thioacetate (9.3 
mmol, 1.06 g, 10 equiv) gave 8b (0.32 mmol, 114 mg, 34%) as 
an orange oil. 1H NMR (400 MHz, Chloroform-d) δ 7.22-7.18 
(m, 2H), 7.12-7.08 (m, 3H), 4.07-4.00 (m, 4H), 3.26 (ddd, J = 
15.2, 13.9, 5.1 Hz, 1H), 2.92 (ddd, J = 13.9, 12.0, 8.2 Hz, 1H), 
2.54 (t, J = 7.3 Hz, 2H), 2.25 (s, 3H), 1.99-1.86 (m, 1H), 1.76-
1.70 (m, 3H), 1.63-1.43 (m, 1H), 1.27-1.23 (m, 6H). 13C NMR 
(101 MHz, Chloroform-d) δ 195.1 , 141.8, 128.3 (dd, J = 16.7, 
1.9 Hz), 125.7, 61.8 (t, J = 6.9 Hz), 37.0, 35.7-35.4 (m), 30.4 (d, 
J = 2.5 Hz), 28.9 (dd, J = 7.3, 2.3 Hz), 28.3 (d, J = 1.9 Hz), 27.4 
(d, J = 3.7 Hz), 16.4 (d, J = 5.8 Hz). 31P NMR (162 MHz, 
Chloroform-d): δ 30.5. HRMS (ESI): Calcd. for C17H28O4PS 
[M+H]+ 359.1440; found 359.1449.  
4 .1 .4 .3 .  S-2- (d ie thoxyphosphory l ) -6 -pheny lhexy l  
e thane th ioa te  (8c ) :  
Diethyl 1-hydroxy-6-phenylhexane-2-ylphosphonate 7c (13 
mmol, 4.20 g, 1 equiv), triethylamine (0.014 mmol, 1.42 g, 1.05 
equiv), methanesulfonyl chloride (1.34 mmol, 152 mg, 1.05 
equiv) ), DMAP (catalytic amount) and potassium thioacetate 
(0.14 mmol, 15.98 g, 10 equiv) gave 8c (9.4 mmol, 3.502 g, 
71%) as an orange oil. 1H NMR (400 MHz, Chloroform-d) δ 
7.34-7.30 (m, 2H), 7.24-7.21 (m, 3H), 4.18-4.15 (m, 4H), 3.38 
(ddd, J = 15.2, 13.8, 5.0 Hz, 1H), 3.03 (ddd, J = 13.9, 11.9, 8.2 
Hz, 1H), 2.67 (t, J = 7.6 Hz, 2H), 2.38 (s, 3H), 2.06-1.97 (m, 1H), 
1.83-1.77 (m, 1H), 1.69-1.62 (m, 3H), 1.62-1.56 (m, 2H), 1.40-
1.36 (m, 6H). 13C NMR (101 MHz, Chloroform-d) δ 195.4, 
142.5, 128.4 (d, J = 13.2 Hz), 125.7, 61.9 (dd, J = 6.9, 5.0 Hz), 
37.2, 35.7 (d, J = 8.9 Hz), 31.5, 30.6, 28.5 (d, J = 1.8 Hz), 27.9 
(d, J = 3.5 Hz), 27.1 (d, J = 7.4 Hz), 16.5 (d, J = 6.0 Hz). 31P 
NMR (162 MHz, Chloroform-d): δ 31.1. HRMS (ESI): calcd. For 
C18H26O4PS [M+H]+ 373.1602; found 373.1289.  
4 .1 .5 .  Deace ty la t ion  o f  th ioace ta tes  (prepara t ion  o f  
1c ,  2a–c  and  4 ) :  
Except for 2a, the following general procedure was applied. 
To a stirred solution of thioacetate (8 or 15) (1 equiv) in 
methanol (6 mL) at -20 °C was added sodiumthiomethoxide, 
NaSMe (1 M solution in MeOH, 1 equiv). The reaction mixture 
was stirred for 30 minutes at -20 °C, before aqu. HCl (0.1 M) was 
added. The reaction mixture was extracted with DCM (3 x 30 
mL), the combined organic layers were washed with brine, dried 
over MgSO4, filtered and concentrate. The resulting crude was 
purified by column chromatography. 
4 .1 .5 .1 .  Die thy l  1 -mercapto -4-pheny lbu tan-2-
y lphosphonate  (2a ) :   
According to the reported procedure, [38] a 0.1 M 
NaOMe/MeOH solution (3 mmol, 3 mL, 2 equiv) was added to 
thioacetate 8a (1.5 mmol, 0.52g, 1 equiv) at 0 ˚C. The resulting 
mixture was stirred for 15 min at rt under H2 and concentrated. 
Aq. NH4Cl (30 mL) and 0.1 M HCl (10 mL) were added to the 
crude and the product was extracted with diethyl ether. The 
combined organics were dried and concentrated. Repeated 
column chromatography (5–20% MeOH: CH2Cl2 and 3:1 
EtOAc:Et2O) gave 2a (0.46 mmol, 139 mg, 30%) as a slightly 
orange oil. 1H NMR (400 MHz, Methanol-d4) δ 7.33-7.29 (m, 
2H), 7.26-7.20 (m, 3H), 4.18-4.10 (m, 4H), 3.04-2.92 (m, 1H), 
2.86-2.72 (m, 4H), 2.15-2.01 (m, 3H), 1.71 (t, J = 8.3 Hz, 1H), 
1.37-1.33 (m, 6H). 13C NMR (101 MHz, Methanol-d4) δ 142.9, 
129.7, 127.3, 63.7 (dd, J = 7.1, 1.9 Hz), 40.5, 39.1, 34.4 (d, J = 
8.2 Hz), 30.2 (d, J = 3.2 Hz), 23.9 (d, J = 2.6 Hz), 16.9 (d, J = 5.8 
Hz). 31P NMR (162 MHz, Choroform- d) δ 32.9. HRMS (ESI): 
Calcd. for C16H28O3PS [M+H]+ 331.1491; found 331.1494. 
4 .1 .5 .2 .  Die thy l  1 -mercapto -5-pheny lpen tan-2-
y lphosphonate  (2b ) :  
Thioacetate 8b (0.56 mmol, 0.20 g, 1 equiv) in methanol and 1 
M NaSMe in MeOH (0.6 mmol, 0.6 mL, 1 equiv) gave 2b (0.41 
mmol, 130 mg, 74%) as white oil after purification with column 
chromatography (5-20% MeOH: CH2Cl2). 1H NMR (400 MHz, 
Chloroform-d) δ 7.29-7.25 (m, 2H), 7.19-7.15 (m, 3H), 4.12-4.04 
(m, 4H), 2.96-2.85 (m, 1H), 2.69-2.62 (m, 3H), 1.98-1.93 (m, 
1H), 1.80-1.76 (m, 4H), 1.65 (t, J = 8.4 Hz, 1H), 1.32-1.28 (m, 
6H). 13C NMR (101 MHz, Chloroform-d) δ 142.0, 128.5 (d, J = 
8.8 Hz), 125.9, 61.9 (dd, J = 7.3, 3.1 Hz), 40.4, 38.9, 35.9, 28.9 
(d, J = 8.2 Hz), 26.7 (d, J = 3.6 Hz), 23.7 (d, J = 2.7 Hz), 16.6 (d, 
J = 6.2 Hz). 31P NMR (162 MHz, Chloroform-d) δ 31.9. HRMS 
(ESI): Calcd. for C15H26O3PS [M+H]+ 317.1335; found 317.1337. 
4 .1 .5 .3 .  Die thy l  1 -mercapto -6-pheny lhexan-2-
y lphosphonate  (2c )  
Thioacetate 8c (1.07 mmol, 400 mg, 1 equiv) in methanol and 
1M NaSMe in MeOH (1.1 mmol, 1.1 mL, 1 equiv) gave 2c (0.82 
mmol, 270 mg, 77%) as a colorless oil after purification with 
column chromatography (5–20% MeOH: CH2Cl2). 1H NMR (400 
MHz, Chloroform-d) δ 7.28-7.23 (m, 2H), 7.17-7.15 (d, J = 6.8 
Hz, 3H), 4.12-4.05 (m, 4H), 2.94-2.83 (m, 1H), 2.70-2.60 (m, 
3H), 1.98-1.80 (m, 1H), 1.76-1.66 (m, 5H), 1.60-1.43 (m, 2H), 
1.30 (t, J = 7.0 Hz, 6H). 13C NMR (101 MHz, Chloroform-d) δ 
142.5, 128.5 (d, J = 11.5 Hz), 125.8, 61.8 (d, J = 6.9 Hz), 40.3, 
38.9, 35.7 (d, J = 1.9 Hz), 31.4, 26.9-26.8 (m), 23.6 (d, J = 2.3 
Hz), 16.6 (d, J = 5.9 Hz). 31P NMR (162 MHz, Chloroform-d) δ 
31.5. HRMS (ESI): Calcd. for C16H28O3PS [M+H]+ 331.1486; 
found 331.1491. 
4 .1 .5 .4 .  5-Pheny l -2 - (1H- te t razo l -5 -y l )pen tane-1-
th io l  (4 )  
Thioacetate 15b (0.1 mmol, 30 mg, 1 equiv) in methanol was 
treated with 1 M NaSMe in MeOH (0.2 mmol, 0.2 mL, 2 equiv). 
The reaction time was 1.5 h at RT. Column chromatography (3% 
MeOH: CH2Cl2) provided 4 as white solid (0.073 mmol, 18.1 mg, 
73%) with high purity (> 95% as determined by HPLC). 1H 
NMR (400 MHz, Methanol-d4) δ 7.19-7.04 (m, 5H), 3.45-3.43 
(m, 1H), 3.04-2.95 (m, 2H), 2.56 (q, J = 7.6 Hz, 2H), 1.82 (ddd, J 
= 35.0, 8.0, 4.1 Hz, 2H), 1.75-1.72 (m, 2H), 1.49-1.36 (m, 2H). 
13C NMR (101 MHz, Methanol-d4) δ 158.3, 141.5, 127.9, 125.5, 
41.1, 35.3, 34.8, 32.7, 28.5. HRMS (ESI): Calcd. for C12H17N4S 
[M+H]+  249.1170; found 249.1168. 
4 .1 .6 .  Genera l  procedure  for  the  hydro lys i s  o f  
phosphonic  es ters  (prepara t ion  o f  3 ,  9  and  10 )  
Bromotrimethylsilane (3 equiv) was added drop wise to 2, 7 or 
8 (1 equiv) in 10 mL dry CH2Cl2 under argon. The mixture was 
stirred overnight at room temperature. The solvent and excess 
TMSBr were removed under reduced pressure, MeOH (0.2 
mL/mmol of substrate) was added and the reaction mixture was 
stirred for 1 h at RT. The reaction mixture was evaporated to 
dryness. The crude 3, 9 or 10 was obtained as viscous oil. Crude 
product was dissolved in minimal volume of EtOAc and cold 
pentane was added resulting in the separation of compound as 
oily or crystalline material. The pentane layer was discarded and 
the remaining compound was dried under vacuum. 
4 .1 .6 .1 .  1-Hydroxy-4-pheny lbu tan-2-y lphosphonic  
ac id  (9a )  
Diethyl 1-hydroxy-4-phenylbutyl-2-ylphosphonate 7a (0.31 
mmol, 95 mg, 1 equiv) and TMSBr (140 mg) gave crude 9a (77 
mg) as a colorless oil. A small batch (30 mg) was dissolved in 2-
3 drops of EtOAc and washed with cold pentane, afforded the 
pure product 9a (0.086 mmol, 20 mg, 76%). 1H NMR (400 MHz, 
Chloroform-d) δ 8.65 (s, 2H), 7.15-7.08 (m, 5H), 3.84-3.80 (m, 
2H), 2.69-2.58 (m, 2H), 2.02-1.80 (m, 2H), 1.78-1.73 (m, 1H). 
13C NMR (101 MHz, Methanol-d4) δ 142.0, 128.0 (d, J = 13.0 
Hz), 125.5, 60.3, 40.5, 39.2, 33.6 (d, J = 8.3 Hz), 28.1 (d, J = 3.2 
Hz), 22.8. 31P NMR (162 MHz, Methanol-d4) δ 26.1. HRMS 
(ESI): Calcd. for C10H16O4P [M+H]+ 231.0781; found: 231.0779. 
4 .1 .6 .2 .  1-Hydroxy-5-pheny lpen tane-2-y lphosphonic  
ac id  (9b ) :  
Diethyl 1-hydroxy-5-phenylpentan-2-ylphosphonate 7b (0.36 
mmol, 0.1 g, 1 equiv) and TMSBr (1.06 mmol, 0.16 g, 3 equiv) 
gave crude 9b (110 mg) as a colourless oil. A small batch (64 
mg) was dissolved in 2-3 drops of EtOAc and washed with cold 
pentane, afforded the pure product 9b (0.16 mmol, 39 mg, 61%). 
1H NMR (400 MHz, Methanol-d4) δ 7.29-7.15 (m, 5H), 3.92 
(ddd, J = 14.3, 11.0, 4.9 Hz, 1H), 3.73-3.64 (m, 1H), 2.68-2.63 
(m, 2H), 1.98-1.69 (m, 5H). 13C NMR (101 MHz, Methanol-d4) δ 
142.2, 127.9 (d, J = 15.9 Hz), 125.3, 60.4, 40.9, 39.5, 35.7, 29.6 
(d, J = 8.3 Hz), 25.8 (d, J = 3.4 Hz). 31P NMR (162 MHz, 
Methanol-d4) δ 31.1. HRMS (ESI): Calcd. for C11H18O4P [M+H]+ 
245.0937; found  245.0936. 
4 .1 .6 .3 .  1-Hydroxy-5-pheny lpen tane-2-y lphosphonic  
ac id  (9c ) :  
Diethyl 1-hydroxy-5-phenylpentan-2-ylphosphonate 7c (0.36 
mmol, 100 mg, 1 equiv) and TMSBr (0.95mmol, 150 mg, 3 
equiv) gave crude 9c (110 mg) as colorless oil. A small batch (38 
mg) was dissolved in 2-3 drops of EtOAc and washed with cold 
pentane, afforded the pure product product 9c  (21 mg, 0.081 
mmol, 55%). 1H NMR (400 MHz, Chloroform-d) δ 8.22 (s, 2H), 
7.27-7.20 (m, 2H), 7.15-7.10 (m, 3H), 3.91-3.74 (m, 2H), 2.57-
2.53 (m, 2H), 1.94-1.73 (m, 1H), 1.69-1.56 (m, 1H), 1.55-1.38 
(m, 5H). 13C NMR (101 MHz, Methanol-d4) δ 142.4, 127.9 (d, J 
= 13.5 Hz), 125.2, 60.3, 40.9, 39.5, 35.3, 31.5, 27.2 (d, J = 8.5 
Hz), 25.7 (d, J = 3.4 Hz). 31P NMR (162 MHz, Methanol-d4) δ 
32.0. HRMS (ESI): Calcd. for C12H19O4PNa [M+H]+ 281.0916; 
found 281.0913. 
4 .1 .6 .4 .  1-Ace ty l th io -4-pheny lbu tan-2-y lphosphonic  
ac id ,  (10a ) :  
S-2-(diethoxyphosphoryl)-4-phenylbutyl ethanethioate 8a 
(0.77 mmol, 268 mg, 1 equiv) and TMSBr (2.31 mmol, 353 mg, 
3 equiv) gave crude 10a (232 mg) as an orange oil. The crude 
was dissolved in 2–3 drops of EtOAc and washed with cold 
pentane, afforded the pure product 10a (0.69 mmol, 201 mg, 
91%).  1H NMR (400 MHz, Methanol-d4) δ 7.26-7.22 (m, 2H), 
7.19-7.14 (m, 3H), 3.44-3.36 (m, 1H), 3.04 (ddd, J = 13.8, 10.4, 
8.4 Hz, 1H), 2.79-2.76 (m, 2H), 2.30 (s, 3H), 2.07-1.81 (m, 3H). 
13C NMR (101 MHz, Methanol-d4) δ 195.5, 141.8 (d, J = 17.5 
Hz), 128.1-128.0 (m), 125.5, 40.4, 39.0, 37.2, 35.8, 33.1 (t, J = 
8.0 Hz), 29.7 (d, J = 2.9 Hz), 28.9 (dd, J = 10.7, 2.5 Hz), 28.0, 
22.9. 31P NMR (162 MHz, Methanol-d4) δ 30.4. HRMS (ESI): 
Calcd. for C12H18O4PS [M+H]+ 289.0658; found 289.0660. 
4 .1 .6 .5 .  1-(Ace ty l th io ) -5 -pheny lpen tan-2-
y lphosphonic  ac id ,  (10b ) :  
S-2-(diethoxyphosphoryl)-5-phenylpentan ethanethioate 8b 
(0.53 mmol, 190 mg, 1 equiv) and TMSBr (1.58 mmol, 242 mg, 
3 equiv) gave crude 10b (207 g) as an orange oil. The crude was 
dissolved in 2-3 drops of EtOAc and washed with cold pentane, 
afforded the pure product 10b (0.37 mmol, 113 mg, 71%). 1H 
NMR (400 MHz, Methanol-d4) δ 7.25-7.13 (m, 5H), 3.39-3.30 
(m, 1H), 3.00 (ddd, J = 14.0, 10.9, 8.5 Hz, 1H), 2.58 (t, J = 7.3 
Hz, 2H), 2.27 (s, 3H), 1.94-1.56 (m, 6H). 13C NMR (101 MHz, 
Methanol-d4) δ 195.4, 141.9, 128.0 (d, J = 18.7 Hz), 125.4, 37.8, 
36.4, 35.4, 29.0 (d, J = 7.4 Hz), 28.0, 27.5 (d, J = 3.1 Hz). 31P 
NMR (162 MHz, Methanol-d4) δ 30.8. HRMS (ESI): Calcd. for 
C13H20O4PS [M+H]+ 303.0814; found 303.0818. 
4 .1 .6 .6 .  1-(Ace ty l th io ) -6 -pheny lhexan-2-
y lphosphonic  ac id ,  (10c ) :  
S-2-(diethoxyphosphoryl)-6-phenylhexyl ethanethioate, 8c 
(0.478 mmol, 0.178 g, 1 equiv) and TMSBr (1.434 mmol, 0.219 
g, 3 equiv) gave crude 10c (113 mg) as an orange oil. The crude 
was dissolved in 2-3 drops of EtOAc and washed with cold 
pentane, afforded the pure product 10c (0.31 mmol, 98 mg, 
65%). 1H NMR (400 MHz, Methanol-d4) δ 7.26-7.20 (m, 3H), 
7.19-7.12 (m, 2H), 3.39-3.33 (m, 1H), 3.04 (ddd, J = 13.8, 10.8, 
8.6 Hz, 1H), 2.65-2.58 (m, 3H), 2.30 (s, 3H), 1.96-1.89 (m, 1H), 
1.82-1.72 (m, 4H), 1.64-1.59 (m, 1H). 13C NMR (101 MHz, 
Methanol-d4) δ 195.5, 141.9, 128.1-127.8 (m), 125.3, 40.9, 39.6, 
37.8, 36.4, 35.5 (d, J = 11.7 Hz), 29.2-28.8 (m), 28.1, 27.5 (d, J = 
3.1 Hz), 26.7 (d, J = 3.0 Hz), 23.0. 31P NMR (162 MHz, 
Methanol-d4) δ 31.5. HRMS (ESI): Calcd. for 
C14H20O4PS[M+H]+ 315.0820; found 315.0817. 
4 .1 .6 .7 .  1-Su l fany l -4 -pheny lbu tan-2-y lphosphonic  
ac id  (3a ) :  
Diethyl 1-sulfanyl-4-phenylbutan-2-ylphosphonate 2a (0.14 
mmol, 43 mg, 1 equiv) and TMSBr (0.43 mmol, 65 mg, 3 equiv) 
gave crude 3a (38 mg) as an orange oil. The crude was dissolved 
in 2–3 drops of EtOAc and washed with cold pentane, afforded 
the pure product 3a (0.13 mmol, 33 mg, 96%).1H NMR (400 
MHz, Chloroform-d) δ 9.05 (s, 2H), 7.28-7.19 (m, 5H), 3.05-2.94 
(m, 1H), 2.78-2.74 (m, 3H), 2.14-2.07 (m, 3H), 1.56 (t, J = 8.4 
Hz, 1H). 13C NMR (101 MHz, Methanol-d4) δ 141.8, 128.1 (d, J 
= 12.3 Hz), 125.6, 40.4, 39.0, 33.1 (d, J = 7.5 Hz), 28.9, 22.9. 31P 
NMR (162 MHz, Methanol-d4) δ 30.43. HRMS (ESI): Calcd. for 
C10H16O3PS [M+H]+ 247.0552; found 247.0552. 
4 .1 .6 .8 .  1-su l fany l -5 -pheny lpen tan-2-y lphosphonic  
ac id  (3b ) :  
Diethyl 1-sulfanyl-5-phenylpentan-2-ylphosphonate 2b (0.05 
mmol, 15 mg, 1 equiv) and TMSBr (0.14 mmol, 22 mg, 3 equiv) 
gave crude 3b as an orange oil. The crude was dissolved in 2-3 
drops of EtOAc and washed with cold pentane, afforded the pure 
product 3b (0.04 mmol, 11 mg, 90%). 1H NMR (400 MHz, 
Methanol-d4) δ 7.27-7.18 (m, 4H), 7.16-7.12 (m, 1H), 2.97 (ddd, 
J = 17.8, 13.7, 3.8 Hz, 1H), 2.66-2.60 (m, 3H), 1.91-1.78 (m, 
5H). 13C NMR (101 MHz, Methanol-d4) δ 142.9, 128.8 (d, J = 
16.9 Hz), 126.1 (d, J = 3.3 Hz), 41.8, 40.4, 36.3, 29.9(d, J = 7.4 
Hz), 27.5 (d, J = 2.5 Hz), 23.8. 31P NMR (162 MHz, Methanol-
d4) δ 30.12. HRMS (ESI): Calcd. for C11H18O3PS [M+H]+ 
261.0709; found 261.0712. 
4 .1 .6 .9 .  1-su l fany l -6 -pheny lhexan-2-y lphosphonic  
ac id ,  (3c ) :  
Diethyl 1-sufanyl-6-phenylhexan-2-ylphosphonate 2c (0.30 
mmol, 100 mg, 1 equiv) and TMSBr (0.91 mmol, 144 mg, 3 
equiv) gave crude 3c as an orange oil. The crude was dissolved in 
2–3 drops of EtOAc and washed with cold pentane, afforded the 
pure product 3c (0.29 mmol, 81 mg, 98%). 1H NMR (400 MHz, 
Chloroform-d) δ 8.59 (s, 2H), 7.29-7.25 (m, 2H), 7.19-7.16 (m, 
3H), 2.98 (ddd, J = 20.0, 13.9, 4.6 Hz, 1H), 2.75-2.63 (m, 1H), 
2.62 (dd, J = 8.8, 6.4 Hz, 2H), 2.11-2.02 (m, 1H), 1.83 (ddd, J = 
16.5, 9.4, 6.2 Hz, 2H), 1.67-1.63 (m, 2H), 1.49-1.47 (m, 2H), 
1.34 (t, J = 7.1 Hz, 1H). 13C NMR (101 MHz, Methanol-d4) δ 
142.5 (d, J = 3.2 Hz), 128.1-127.9 (m), 125.2, 41.3 (d, J = 134.8 
Hz), 35.3, 31.5-31.4 (m), 26.9-26.9 (m), 23.3. 31P NMR (162 
MHz, Methanol-d4) δ 30.5. HRMS (ESI): Calcd. for 
C12H19O3NaPS [M+H]+ 297.0690; found 297.0685. 
4 .1 .7 .  Genera l  procedure  for  the  syn thes i s  o f  
acry lon i t r i les  (13a  and  13b )  
Compound 13a and 13b were prepared by a modified 
procedure based on the work of Baraldi et al. [39] K2CO3 (3 
equiv) and 4-cyano-3-oxotetrahydrothiophene 12 (1 equiv) were 
stirred in dry acetone (20 mL). To this suspension alkyl halide (1 
equiv) was added and the mixture was refluxed for 5 h. The 
residue was dissolved in ether and stirred vigorously with 5% 
NaOH aq. (10 mL). The solution was kept at RT until complete 
fragmentation of the intermediate adduct was observed by TLC. 
The organic phase was separated and dried with sodium sulfate. 
The crude oil was further purified by column chromatography 
using 20% diethyl ether in pentane as eluent.  
4 .1 .7 .1 .  2-Benzy lacry lon i t r i le  (13a ) :  
K2CO3 (11.7  mmol, 1.62 g, 3 equiv), compound 4-cyano-3-
oxotetrahydrothiophene (3.9 mmol, 0.5 g, 1 equiv), and benzyl 
bromide (3.9 mmol, 0.673 g, 1 equiv), gave 13a as an oil (1.99 
mmol, 284 mg, 51%). 1H NMR (400 MHz, Chloroform-d) δ 7.40 
(t, J = 8.0 Hz, 2H), 7.33 (d, J = 7.3 Hz, 1H), 7.26 (d, J = 7.4 Hz, 
2H), 5.95 (s, 1H), 5.73 (s, 1H), 3.59 (s, 2H). 13C NMR (101 MHz, 
Chloroform-d) δ 135.6, 131.1, 129.2, 128.9, 128.9, 128.6, 128.6, 
128.4, 127.4, 122.7, 118.5, 40.8. HRMS (ESI): Calcd. for 
C10H10N [M+H]+ 144.0808; found 144.0808. 
4 .1 .7 .2 .  2-Methy lene-5-pheny lpen tanen i t r i le  (13b ) :   
K2CO3 (47.1 mmol, 6.51 g, 3 equiv), 4-cyano-3-
oxotetrahydrothiophene (15.7 mmol, 2.00 g, 1 equiv), 1-bromo-
3-phenylpropane (15.7 mmol, 3.13 g, 1 equiv), gave 13b as an oil 
(3.29 mmol, 564 mg, 21%). 1H NMR (400 MHz, Chloroform-d) 
δ 7.34 (dd, J = 8.1, 6.7 Hz, 2H), 7.24-7.19 (m, 3H), 5.87 (s, 1H), 
5.71 (d, J = 1.6 Hz, 1H), 2.68 (t, J = 7.6 Hz, 2H), 2.29-2.27 (m, 
2H), 1.96-1.90 (m, 2H), . 13C NMR (101 MHz, Chloroform-d) δ 
141.1, 130.5, 128.5, 128.5, 128.4, 126.1, 122.9, 118.6, 34.7, 33.9, 
29.1. HRMS (ESI): Calcd. for C12H14N4 [M+H]+ 172.1114; found 
172.1121. 
4 .1 .7 .3 .  4 .1 .8  Genera l  procedure  for  the  
prepara t ion  o f  t e t razo les  (14a  and  14b )  
Dibutyltin oxide (0.2 equiv) and trimethylsilyl azide (2 equiv) 
were added to a solution of 13 (1 equiv) in anhydrous 1,4-
dioxane (2 mL/mmol). The reaction mixture was subjected to 
microwave irradiation in a tightly sealed vessel for 50 min at 150 
0C, then cooled to room temperature. The solvent was removed 
under reduced pressure. The residue was dissolved in diethyl 
ether (10 mL and extracted with 2 M aq. NaOH (3 x 10 mL). The 
aqueous layer was acidified with 4 M aq. HCl to pH 1 and 
extracted with ethyl acetate (4 x 10 mL). The organic extract was 
washed with brine (10 mL), dried over MgSO4, and evaporated 
under reduced pressure to give the target tetrazoles, which were 
recrystallized from EtOAc. 
4 .1 .7 .4 .  5-(3-pheny lprop-1-en-2-y l ) -1H- te t razo le  
(14a ) :  
Dibutyltin oxide (0.07 mmol, 0.017 g, 0.2 equiv), 
trimethylsilyl azide (1.4 mmol, 0.161 g, 2 equiv) and 13a (0.100 
g, 0.7 mmol, 1 equiv) gave 14a (0.55 mmol, 102 mg, 78%). 1H 
NMR (400 MHz, Methanol-d4) δ 7.35-7.18 (m, 5H), 6.04 (s, 1H), 
5.47 (s, 1H), 4.92 (s, 1H), 3.92 (s, 2H). 13C NMR (101 MHz, 
Methanol-d4) δ 137.5, 133.2, 128.7, 128.1, 126.3, 120.3, 38.9. 
HRMS (ESI): Calcd. for C10H10N4 [M+H]+ 187.0981; found 
187.0978. 
4 .1 .7 .5 .  5-(5-Pheny lpen t -1 -en-2-y l ) -1H- te t razo le  
(14b ) :  
Dibutyltin oxide (0.58 mmol, 145.39mg, 0.2 equiv), 
trimethylsilyl azide (5.84 mmol, 0.672 g, 2 equiv) and 13b (2.92 
mmol, 1 equiv) gave 14b (2.16 mmol, 462 mg, 74%). 1H NMR 
(400 MHz, Chloroform-d) δ 7.14-7.00 (m, 5H), 5.87 (s, 1H), 5.47 
(t, J = 1.4 Hz, 1H), 4.84-4.83 (m, 1H), 2.58 (dd, J = 15.7, 7.8 Hz, 
4H), 1.78 (m, 2H). 13C NMR (101 MHz, Chloroform-d) δ 157.3, 
143.1, 134.7, 129.4, 129.4, 126.9, 120.6, 36.2, 34.0, 30.9. HRMS 
(ESI): Calcd. for C12H15N4 [M+H]+ 215.1292; found 215.1291. 
4 .1 .8 .  Genera l  procedure  for  the  Michae l  add i t ion  
to  v iny l ic  te t razo les  (prepara t ion  o f  15  and  16 )  
Vinylic tetrazole 14 (1 equiv) and thioacetic acid (26 equiv) or 
thiol (4 equiv) were dissolved in anhydrous DMF. The reaction 
mixture was subjected to heating at 60 0C in a tightly sealed 
vessel for 22 h with stirring. The solvent was removed under 
reduced pressure and the crude was subjected to column 
chromatography using 5% MeOH in CH2Cl2. 
4 .1 .8 .1 .  S-(3-Pheny l -2 - (1H- te t razo l -5 -y l )propy l )  
e thane th ioa te  (15a )  
14a (0.32 mmol, 0.060 g, 1 equiv), and thioacetic acid (8.6 
mmol, 0.662 g, 26 equiv) gave 15a (0.30 mmol, 79 mg, 95%) as 
a colorless oil. 1H NMR (400 MHz, Chloroform-d) δ 7.20-7.16 
(m, 3H), 7.08-7.06 (m, 2H), 3.86 (q, J = 10.5, 7.7 Hz, 1H), 3.44-
3.40 (m, 1H), 3.33 (d, J = 14.0 Hz, 1H), 3.23 (d, J = 7.6 Hz, 2H), 
2.27 (s, 3H). 13C NMR (101 MHz, Chloroform-d) δ 195.9, 157.9, 
137.0, 128.9, 128.9, 128.7, 127.0, 39.7, 38.0, 31.8, 30.6. HRMS 
(ESI): Calcd. for C12H15ON4S [M+H]+ 263.0964; found 
263.0961. 
4 .1 .8 .2 .  S-(5-pheny l -2 - (1H- te t razo l -5 -y l )pen ty l )  
e thane th ioa te  (15b )  
14b (0.466 mmol, 0.100 mg, 1 equiv), and thioacetic acid 
(12.1 mmol, 0.925 g, 26 equiv) gave 15b (0.456 mmol, 132 mg, 
98%) as a colorless oil. 1H NMR (400 MHz, Methanol-d4) δ 
7.22-7.11 (m, 5H), 4.93 (s, 1H), 3.38-3.30 (m, 2H), 3.16 (dd, J = 
15.2, 10.3 Hz, 1H), 2.58 (t, J = 7.5 Hz, 2H), 2.24 (s, 3H), 1.91-
1.77 (m, 2H), 1.61-1.45 (m, 2H). 13C NMR (101 MHz, Methanol-
d4) δ 196.2, 159.6, 142.9, 129.4, 126.9, 37.2, 36.2, 33.9, 33.3, 
30.4, 29.9. HRMS (ESI): Calcd. for C14H19ON4S [M+H]+ 
291.1284; found 291.1274. 
4 .1 .8 .3 .  ´5 - (1 - (cyc lohexy l th io ) -5 -pheny lpen tan-2-
y l ) -1H- te t razo le  (16 )  
14a (0.23 mmol, 0.050 g, 1 equiv), and cyclohexyl thiol 
(0.933 mmol, 0.108 g, 4 equiv) gave 16 (0.216 mmol, 71.50 mg, 
93%). 1H NMR (400 MHz, Methanol-d4) δ 7.23-7.09 (m, 5H), 
2.95-2.82 (m, 1H), 2.58-2.55 (m, 2H), 1.86-1.68 (m, 6H), 1.59-
1.18 (m, 10H). 13C NMR (101 MHz, Methanol-d4) δ 158.94, 
141.6, 127.9, 127.9, 125.5, 43.6, 36.7, 34.9, 33.6, 33.4, 33.3, 
32.8, 28.6, 25.6, 25.5. HRMS (ESI): Calcd. for C18H27N4S 
[M+H]+ 331.1950; found 331.1951. 
4.2. Biological activity 
4 .2 .1 .  Gene  Cons truc ts  o f  VIM-2 ,  NDM-1 and  GIM-
1  
In this study two types of gene constructs were used. The first 
included the native leader sequence to allow the proteins to be 
transported to the periplasm, for the three enzymes VIM-2 from 
Pseudomonas aeruginosa strain 301-5473 (GenBank no 
Q9K2N0; [51]), GIM-1 from P. aeruginosa (GenBank no 
Q704V1; [50, 52]) and NDM-1 (GenBank no. E9NWK5, e.g [53, 
54]), where the latter blaNDM-1 gene is reported from several 
organisms. Cloning of blaNDM-1 or blaGIM-1 genes into the 
Escherichia coli pET26b(+) vector (Novagen) was performed 
using the Primers listed in Table S3, and by restriction cutting as 
described for VIM-26. [55] Cloning of blaVIM-2 into 
pET26b(+)are described previously. [56] The obtained E. coli 
pET-26b(+) MBL constructs were further used in the in the 
whole cell-based inhibitor assays.  
In the second gene constructs used for the recombinant gene 
expression, the native leader sequence was removed and replaced 
with a hexa-His tag and a TEV cleavage site as reported earlier 
for VIM-2 (residues V27-E268; [57]) and GIM-1 (residues Q19-
D250; [50]) both in pDEST14. NDM-1 used a codon optimized 
synthetic gene (Life Technologies, Thermo Fisher Scientific), 
with a TEV cleavage site with sequence ENLYFQG and residues 
G36-R280 in NDM-1 transformed in pDONR™221, and further 
sub cloned into pDEST17 with carries an N-terminal hexa His-
tag, yielding pDest17-NDM-1. Herein the residue numbering is 
the class B β-lactamase numbering scheme will be applied [10]. 
4 .2 .2 .  Recombinant  pro te in  express ion  and  
pur i f ica t ion  o f  VIM-2 ,  GIM-1  and  NDM-1 
The three proteins were expressed and purified following this 
protocol. pDest17-NDM-1 was transformed into E. coli BL21 
Star (DE3) pLysS (Invitrogen), and pDEST14 plasmids with 
VIM-2 or GIM-1 were transformed into in-house modified E. 
coli BL21 Star (DE3) pLysS (Invitrogen) cells with the pRARE 
plasmid (Novagen) in order to allow expression of genes 
encoding tRNAs for rare codons [58]. Precultures grown in 
Terrific Broth (TB) media with 100 µg/ml ampicillin (Sigma-
Aldrich) and 34 µg/ml chloramphenicol (Sigma-Aldrich). The 
precultures were inoculated to 2 L Luria-Bertani (LB) media 
containing 100 µg/ml ampicillin and 34 µg/ml chloramphenicol 
and grown at 37 °C to reach an optical density (OD600 nm) of 0.5-
1.0 before induced expression with 0.4 mM isopropyl β-D-1-
thigalactopyranoside (IPTG; Sigma-Aldrich). The induced 
cultures were grown overnight at 20 °C before collecting the cells 
by centrifugation (8,900 X g, 30 min, 4 °C). Buffer A containing 
50 mM HEPES pH 7.2, 100 µM ZnCl2 and 150 mM NaCl was 
used to resuspend the cell pellets, following sonication and 
collecting the supernatants by centrifugation (3000 g, 40 min, 4 
°C). The recombinant proteins were affinity purified using a 1 ml 
or 5 ml His-Trap HP column (GE Healthcare) in buffer A washed 
with 5% buffer B (50 mM HEPES pH 7.2, 100 µM ZnCl2, 150 
mM NaCl and 1 M imidazole), before eluted in a gradient of 5 to 
100% buffer B. Peak fractions were investigated using 4–20% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE; Bio-Rad) [59]. The peaks containing MBL protein was 
added in-house-made His-tagged TEV protease in a 1:100 mg 
ratio of TEV:protein and dialyzed at 4 °C overnight using 10-kDa 
cutoff Snakeskin (Pierce) in buffer C (50 mM HEPES pH 7.2, 
150 mM NaCl, 1 mM EDTA and 1 mM β-mercaptoethanol). To 
remove uncleaved protein and TEV protease a second His-Trap 
purification was performed. SDS-PAGE analysis was used to 
estimate a purity of ~95% of the fractions containing protein, 
which then were pooled and dialyzed in buffer A overnight. 
4 .2 .3 .  Co-crys ta l l i za t ion  o f  VIM -2  wi th  2b ,  10b  and  
10c   
Co-crystallization of VIM-2 was successful with inhibitors 2b, 
10b and 10c, when applying our new protocol for DMSO free co-
crystallization [45]. MRC 96-wells were pre-coated with 3 µL 
inhibitor (100 mM) dissolved in DMSO, and DMSO evaporated 
after leaving the plates in the fume hood for 24 hours. 60 µL 
reservoir solution consisting of 22-27% PEG 3350 and 0.2 M 
magnesium formate was added to each well. The crystallization 
plates were then shaken for 24 hours to allow the inhibitors to 
dissolve, followed by manual mixing of hanging drops in a 1:1 
ratio of VIM-2 (9.4 mg/ml) and reservoir. The crystals were 
cryoproceeded in 25% PEG 3350, 0.2 M MgCl2, 15% ethylene 
glycol and 50 mM HEPRS pH 7.2, before they were flash cooled 
in liquid nitrogen and X-ray data collected at ESRF, ID29.  
Coordinate and structure factor files for the VIM-2_2b (PDB 
accession number 5MM9), VIM-2_10b (PDB accession number 
5NHZ) and VIM-2_10c (PDB accession number 5NI0) were	  
deposited	  in the Protein Data Bank (PDB). 
4 .2 .4 .  Dose  Rate  Inh ib i t ion  S tud ies  for  IC 5 0  
Determina t ion  
The half-maximal inhibitory concentration (IC50) against the 
VIM-2, NDM-1 and GIM-1 enzymes were determined by using 
sixteen different concentration of inhibitor compounds ranging 
from 0 µM to 250 µM. A 100 µl solution with 50 mM HEPES 
buffer (pH 7.2), 100 µM ZnCl2), purified enzyme (10 nM VIM-2, 
NDM-1 or GIM-1) and 2.5-0 mM inhibitor was incubated in a 96 
well plate at 25 °C for 5 min. In addition, the enzyme buffer 
contained 400 µg/ml Bovine Serum Albumin (BSA) to prevent 
protein unfolding and loss of activity due to low concentrations 
[60, 61]. 100 µM of the reporter substrate nitrocefin (VIM-2, 
GIM-1) or imipenem (NDM-1) was added to the enzyme-
inhibitor solution and the increase in absorbance at 482 nm 
(nitrocefin) or 260 nm (imipenem) was recorded on a Spectramax 
M2e spectrophotometer (Molecular Devices). Each data point 
was performed in triplicates and the initial velocity for each 
inhibitor concentration was analyzed by a log [inhibitor] vs. 
response curve fitting to calculate IC50 in GraphPad Prism 5.0 
software. 
4 .2 .5 .  Cel l -based  screen ing  assay  o f  the  inh ib i t ion  
po ten t ia l    
The inhibitory activity of the inhibitors was investigated in a 
cell-based assay using a β-lactamase-negative E. coli SNO3 
(ampA1	   ampC8	   pyrB	   recA	   rpsL) (24) transformed with 
pET26b(+) containing blaVIM-2, blaGIM-1 or blaNDM-1. The screen 
was conducted in 96-well plates (Corning) in duplicates. One µl 
inhibitor (final concentration 250 µM), 50 µl overnight culture 
(adjusted to an OD600 of 1 in LB broth) of E.	   coli	   SNO3 
containing one of the MBLs and 50 µl LB media with final 
concentration 0.8 mM Isopropyl ß-D-1-thiogalactopyranoside 
(Sigma, IPTG) was added to each well. The plate was incubated 
at 37 °C for 20 min with shaking to induce the expression of the 
MBL. Subsequently, 50 µl nitrocefin (diluted in 50 mM HEPES 
pH 7.2 and 100 µM ZnCl2 to give a final concentration of 1.6 
mM in the assay) was added. Nitrocefin hydrolysis was measured 
at OD482 every minute for 3 hours with shaking (47 seconds) in 
between reads using a Spectramax M2e spectrophotometer 
(Molecular Devices). EDTA (250 µM concentration) was used as 
positive control and wells containing no inhibitor as negative 
controls. The percent inhibition was calculated according to 
equation 1. 
% inhibition = (Slopesample – SlopeAverage negative control) x 100 % 
        (1) 
The synergistic effect of the inhibitors with meropenem was 
tested against selected clinical bacterial strains containing MBLs. 
The bacterial strains were plated on lactose agar plates with 100 
mg/L ampicillin and lactose agar and incubated overnight at 37 
°C. The inhibitors were diluted to a final concentration of 125 
µM in Mueller Hinton (MH) broth. In order to monitor the effect 
of the DMSO in the assay, a DMSO control was included with a 
concentration of 5%. Meropenem was diluted in MH broth in a 2-
fold dilution series with final concentrations of 256 µg/mL – 
0.0625 µg/mL. The microtiter plates were inoculated with a 0.5 
McFarland suspension of the bacterial strain in 0.85% NaCl, 
which were diluted in MH broth. A quality check of bacterial 
suspension in 0.85% NaCl in a 1:100 ratio was incubates on MH 
agar plates overnight at 37 °C. The final CFU/mL inoculum were 
calculated and compared to a standard. The microtiter plates were 
incubated for 20 hours at 37 °C. The minimum inhibitory 
concentrations (MIC) were read visually of the plates the next 
day. 
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